Video

Reactions to Pharmacy Times Health-System Edition

Author(s):

Stephen F. Eckel

Stephen F. Eckel, PharmD, MHA, Pharmacy Times Health-System Edition editor discusses the overall reactions he has heard surrounding Pharmacy Times Health-System Edition.

Stephen F. Eckel, PharmD, MHA, Pharmacy Times Health-System Edition editor and associate professor at the Eshelman School of Pharmacy at UNC discusses the overall reactions he has heard surrounding Pharmacy Times Health-System Edition.

This video was recorded at APhA's Annual Meeting and Exposition in March 2015.

Related Videos
Related Content
Concept of FDA Food and Drug Administration - Image credit: wladimir1804 | stock.adobe.com
December 22nd 2024

Selective Antisense Oligonucleotide-based JAK2 Inhibitor Receives FDA Orphan Drug Designation for Polycythemia Vera

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

FDA website homepage -- Image credit: Postmodern Studio | stock.adobe.com
December 21st 2024

FDA Approves Alyftrek, Once-Daily CFTR Modulator for Cystic Fibrosis

Gillian McGovern, Assistant Editor
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
Sleepless, man suffering from insomnia, sleep apnea or stress. Tired and exhausted guy. Headache or migraine. Awake in the night.
December 20th 2024

FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity

Luke Halpern, Assistant Editor
FDA Approval, Weight Loss, Pediatrics | Image Credit: Aquir | stock.adobe.com
December 20th 2024

FDA Approves Expanded Indication for Setmelanotide to Include Patients 2 and Older

Ashley Gallagher, Associate Editor